# Clinical Trials Data EGFR - Document 15

# Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01719380

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Metastatic colorectal cancer\n\* Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens\n\* Life expectancy \u2265 3 months\n\* ECOG performance status \u2264 2\n\nExclusion Criteria:\n\n\* Symptomatic or untreated leptomeningeal disease\n\* Symptomatic brain metastasis\n\* Patients with clinically manifested diabetes\n\* Acute or chronic pancreatitis\n\* Clinically significant cardiac disease\n\nOther protocol-defined inclusion/exclusion criteria may apply.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no mention of exclusion based on EGFR gene mutations. The inclusion and exclusion criteria focus on the type and progression of the cancer, the patient's performance status, and the presence of certain other medical conditions. Therefore, if a patient meets all the other criteria outlined (having metastatic colorectal cancer, appropriate performance status, etc.), an EGFR gene mutation should not exclude them from participating in this trial. However, there may be other protocol-defined criteria not listed that could affect eligibility, so it would be important to review the full clinical trial protocol or consult the trial investigators for any additional specific exclusion factors related to EGFR mutations.